Definitive Contract HDTRA106C0029

Award Date 9/19/06
Potential Completion Date 9/18/11
Potential Value $27M
Awardee
Evolva AG
Ultimate Awardee
Not listed
NAICS Category
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Switzerland
Solicitation Procedures
Basic Research
Number Of Offers Received
130
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Threat Reduction Agency (DTRA), a defense agency, to Sanofi Pasteur Vaxdesign Corp, a for-profit foreign-owned organization. The contract is a Cost Plus Fixed Fee Definitive Contract with a ceiling value of $10,779,939.95 and an ultimate completion date of March 24, 2018. The contract was awarded on March 21, 2013 and does not have a set-aside designation. The contract is for the BASE YEAR, indicating it may be part of a larger contract...
This is a $2,594,319.91 federal contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of novel small molecule therapeutics to treat infections by Ebola and Marburg viruses. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a period of performance ending on December 14, 2020. Microbiotix has subcontracted with the Albert Einstein College of Medicine...
This is a $12,088,564.69 cost-plus-fixed-fee contract awarded by the Defense Threat Reduction Agency (DTRA) to Amentum Services, Inc., doing business as AECOM, for advisory and assistance services. The contract has a period of performance through May 5, 2025. DTRA is a combat support agency that enables the Department of Defense and U.S. government to counter and deter weapons of mass destruction and emerging technological threats. This contract was awarded as a sole-source, not-to-exceed...
This is a federal contract award from the Defense Threat Reduction Agency (DTRA) to Science Applications International Corporation (SAIC), a large prime contractor, for $47,971,127.64 in language support services. The contract has a period of performance through February 27, 2024 and is a cost-plus-fixed-fee delivery order contract. SAIC has subcontracted portions of the work to several companies, including Fisher Scientific, Safeware, Government Scientific Source, and others, to provide...
This is a cost-plus-fixed-fee delivery order contract awarded by the Defense Threat Reduction Agency (DTRA) to Leidos, Inc., a prominent global technology and engineering solutions provider. The $83,661,819.68 contract is part of DTRA's Combating Weapons of Mass Destruction R&D program, which focuses on strategic systems defense. The contract has no set-aside designation, indicating Leidos' status as a large, capable government contractor. Major subcontractors include Xometry, Inc. (a...
This is a $45,359,554.17 cost-plus-fixed-fee contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Sarepta Therapeutics, Inc. for the development of a new antiviral (antisense) product. The contract was awarded on November 29, 2006 with a completion date of February 28, 2011. The contract does not have a set-aside designation. Sarepta Therapeutics, Inc. is the prime contractor, and there is no information provided about major subcontractors. The DTRA is the funding...
This is a $39,852,548.00 cost-plus-fixed-fee contract awarded by the Defense Threat Reduction Agency (DTRA) to ManTech Advanced Systems International, Inc. for a research and development effort to improve counter-terrorism capabilities. The contract is a definitive contract with an ultimate completion date of April 18, 2027. It is not a set-aside contract. The contract originated from a Broad Agency Announcement (BAA) issued by DTRA, which solicited innovative research and development...
The Defense Threat Reduction Agency awarded PTC Therapeutics, Inc., doing business as PTC, a $18,613,510.19 cost-plus-fixed-fee definitive contract on September 22, 2006 to support the agency's programs. The contract has a completion date of September 21, 2009 and calls for work to be performed in South Plainfield, New Jersey. As a definitive contract issued by DTRA, this vehicle likely funds research, development, testing, and evaluation efforts aimed at countering weapons of mass destruction...
This is a delivery order contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Engility Corporation. The contract has a ceiling value of $2,048,621.00 and is a cost-plus-fixed-fee type contract. The place of performance is Simi Valley, California. This contract does not have a set-aside designation. The contract supports the base period of performance, with a completion date of October 30, 2013. Engility Corporation is the prime contractor, and the parent company...
This definitive contract, awarded by the Defense Threat Reduction Agency (DTRA) to Teledyne Flir Defense, Inc., is for the development of digital battlefield chemical and biological threat mapping and augmented reality display capabilities. The $25,567,855.01 cost-plus-fixed-fee contract has an ultimate completion date of December 31, 2025. This award is not designated as a small business set-aside. The contract is based on a Broad Agency Announcement (BAA) released by DTRA, which sought...

This is a $26,866,882.00 Cost Plus Fixed Fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to Evolva AG, a foreign-owned for-profit manufacturer, for the discovery and development of small molecules. The contract does not have a set-aside designation and has an ultimate completion date of September 18, 2011. As DTRA is a defense agency, this contract is likely supporting the agency's mission to counter weapons of mass destruction. The broad description of "small molecules discovery & development" suggests the contract may be focused on research and development of chemical compounds with potential defense or pharmaceutical applications.

Generated 3/29/25, 10:08 AM